Highest-materiality recent filing
Avalo Therapeutics appoints Ron Philip to Board of Directors
Ron Philip appointed to board effective June 23, 2026; will serve until 2027 annual meeting.
Avalo Therapeutics expands pipeline with AVTX-010, a long-acting anti-IL-1β mAb; IND planned H1 2027
AVTX-010 is an engineered anti-IL-1β mAb for hidradenitis suppurativa and other inflammatory disorders.
Avalo exchanges Series C shares to lift beneficial ownership cap; revises exec severance
Exchanged 4,294.675 Series C shares for new Series C-1 shares, removing restriction that capped beneficial ownership at 4.99% (now 9.99%).
Avalo Therapeutics shareholders approve Second Amended ESPP at 2026 annual meeting
ESPP share reserve set at 961,608 shares; annual evergreen of lesser of 4M shares or 1% of outstanding common stock through 2036.
Avalo reports Q1 net loss $19.6M, Phase 2 HS trial meets endpoints, $431M offering
Phase 2 LOTUS topline: HiSCR75 absolute improvement 42.2% (150mg) and 42.9% (300mg) vs placebo 25.6%; p=0.018 and 0.015.
Avalo Therapeutics raises ~$405M in public offering; preliminary cash $82M as of March 31
Offering of 19.73M shares at $17.75/share plus 1.4M pre-funded warrants at $17.749/warrant.
Abdakibart 150 mg achieved 42.2% HiSCR75 (p=0.018), 300 mg achieved 42.9% (p=0.015); placebo 25.6%.
Avalo Therapeutics buys option to reduce AlmataBio milestone from $15M to $7.375M
Pays $2.25M upfront for 90-day option to pay $5.125M (cash/stock) in lieu of $15M Phase 3 dosing milestone.
Two Avalo Therapeutics directors to not stand for re-election at 2026 Annual Meeting
Dr. Jonathan Goldman and Mitchell Chan will not stand for re-election to the Board at the 2026 Annual Meeting.
Avalo Therapeutics reports 2025 net loss of $78.3M; Phase 2 HS topline data due Q2 2026
Net loss $78.3M ($5.84 per share) vs $35.1M in 2024; operating expenses rose to $73M.
Avalo Therapeutics estimates $98M cash as of Dec 31, 2025 in preliminary update
Preliminary cash, cash equivalents and short-term investments of ~$98M as of December 31, 2025.
Avalo posts updated investor presentation; no specific new data disclosed
Company filed 8-K announcing updated investor presentation posted on its website.
Avalo Therapeutics Q3 net loss $30.6M; completes Phase 2 LOTUS enrollment for AVTX-009
Completed enrollment in Phase 2 LOTUS trial (~250 adults) for AVTX-009 in hidradenitis suppurativa; topline data expected mid-2026.
Avalo completes Phase 2 LOTUS enrollment for AVTX-009; topline data mid-2026
Enrolled ~250 patients, exceeding the 222-patient target.
Avalo Therapeutics posts updated investor presentation; no material new data disclosed
Presentation dated October 2025 describes pipeline of novel IL-1β therapies.
Avalo Therapeutics expands leadership with CBO and SVP HR appointments
Taylor Boyd named Chief Business Officer; base salary $465k, target bonus 40%, 275k stock option inducement grant.
Avalo Therapeutics appoints Kevin Lind to Board effective Oct 1; Dr. Almenoff resigns
Kevin Lind appointed to Board effective Oct 1, 2025; will serve on Audit Committee and receive option for 40,200 shares vesting over 3 years.
Avalo Q2 2025 net loss $20.8M; cash $113.3M; Phase 2 LOTUS >75% enrolled, topline mid-2026
Net loss of $20.8M in Q2 2025 ($1.92 per share) compared to net income of $98.5M ($4.21 basic EPS) in Q2 2024, driven by warrant-related items.
Avalo posts updated investor presentation highlighting IL-1β pipeline focus
Presentation dated June 2025 reiterates mission to advance novel IL-1β therapies for unmet medical needs.
Avalo Therapeutics appoints former ChemoCentryx CMO Rita Jain to board
Dr. Rita Jain appointed to Avalo's Board of Directors effective June 17, 2025.
All eight director nominees elected; top vote-getter Michael Heffernan with 8,022,534 shares for.
Entered Sales Agreement with TD Cowen for at-the-market offering of up to $75M in common stock.
Avalo Therapeutics posts updated investor presentation; content not disclosed in filing
Company posted updated investor presentation on its website on June 4, 2025.
Avalo Q1 net loss $13.1M; cash $125M; Phase 2 HS data expected 2026
Net loss $13.1M ($1.25/shr) vs $121.3M in Q1 2024; prior-year included warrant and acquisition charges.
Avalo posts updated investor presentation; no material new facts disclosed
Company posted an updated investor presentation on its website on May 8, 2025.
Avalo Therapeutics appoints Michael Heffernan as Chairman, separating roles from CEO Garry Neil
Michael Heffernan appointed Chairman of the Board, effective March 25, 2025; succeeds Dr. Garry Neil who remains CEO and Board member.
Avalo reports 2024 net loss of $35.1M; cash of $134.5M funds into at least 2027
Cash and equivalents $134.5M at Dec 31, 2024 vs $7.4M in 2023; runway into at least 2027.
Avalo Therapeutics posts updated investor presentation; no specific financial details disclosed
Avalo posted an updated corporate presentation on its website on Jan 13, 2025.
Avalo Therapeutics appoints Jennifer Riley as Chief Strategy Officer; grants 150k stock option
Jennifer Riley appointed Chief Strategy Officer effective Jan 1, 2025; oversees corporate strategy and pipeline planning.
Avalo Therapeutics posts updated investor presentation; no material new details available
Avalo Therapeutics posted an updated investor presentation on its website on December 5, 2024.
Avalo receives $69.4M from full warrant exercise; cash runway into at least 2027
Gross proceeds of $69.4M from exercise of 11,967,526 warrants at $5.796933/share; total private placement proceeds now $185M.
Avalo Q3 net income $23M; first patient dosed in Phase 2 LOTUS trial for HS
Net income of $23.0M for Q3 2024 vs net loss of $5.2M in Q3 2023; diluted net loss per share $2.83.
Avalo doses first patient in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa
Phase 2 LOTUS trial enrolling ~180 adults with moderate to severe hidradenitis suppurativa.
Avalo posts updated investor presentation; no material new information disclosed
Filed 8-K on Sept 9, 2024 to announce availability of an updated investor presentation.
Avalo Therapeutics regains Nasdaq compliance on market value standard; matter closed
Received written confirmation from Nasdaq on Sept 3, 2024 that market value exceeded $35M for 10 consecutive trading days.
Avalo shareholders approve equity plan increase to 3.55M shares, ESPP, and elect directors
Stockholders approved Fourth Amended and Restated 2016 Equity Incentive Plan, increasing share reserve to 3,548,882 shares with automatic annual increases through 2034.
Cash and cash equivalents $93.4M as of June 30, 2024; expected cash runway into 2027.
Nasdaq grants Avalo Therapeutics 180-day extension to regain equity compliance
Reported stockholders' equity of negative $112.5M as of March 31, 2024, falling short of Nasdaq's $2.5M minimum.
Avalo Therapeutics appoints Mittie Doyle, M.D., as CMO; grants 234,000-share option
Dr. Doyle, former CMO at Aro Biotherapeutics, brings over 20 years of pharma/biotech experience.
FDA cleared IND for AVTX-009 (anti-IL-1β mAb) allowing Phase 2 LOTUS trial in moderate-to-severe HS.
Avalo amends 8K to restate AlmataBio 2023 financials; net loss up $153K
Restated AlmataBio net loss for April 28–Dec 31, 2023 to $812K from $659K, a $153K increase.
Avalo Therapeutics posts updated investor presentation; no specifics available
Company posted an updated corporate presentation on its website dated June 2024.
Avalo Therapeutics Appoints Paul Varki as Chief Legal Officer; Grants Inducement Stock Option
Paul Varki appointed Chief Legal Officer effective June 24, 2024; 20+ years pharma/biotech legal experience.
AlmataBio net loss of $659k from inception (April 28, 2023) to Dec 31, 2023; cash $1.8M, total assets $1.8M.
Avalo Therapeutics receives Nasdaq delisting notice for negative stockholders' equity of $112.6M
Reported stockholders' equity of negative $112.6M in Q1 2024 10-Q, below $2.5M minimum.
Avalo Q1 net loss $121.3M driven by warrant fair value charge; cash $110M into 2027
Cash and cash equivalents $110.2M at March 31, 2024; expects runway through AVTX-009 Phase 2 data readout and into 2027.
Avalo acquires AVTX-009 anti-IL-1β mAb, closes $115.6M private placement; 2023 net loss $31.5M
Acquired AVTX-009 (anti-IL-1β mAb) via acquisition of AlmataBio for $15M in stock plus $7.5M at close; milestones up to $20M.
Avalo acquires Phase 2-ready anti-IL-1β mAb via merger with AlmataBio, raises $115.6M PIPE
Acquired AlmataBio for ~$15M in stock (171,605 common shares + 2,412 Series C Preferred), plus up to $27.5M in milestones.
Avalo regains Nasdaq minimum bid compliance; subject to 1-year panel monitor
Received Nasdaq letter January 30, 2024 confirming compliance with $1.00 bid price rule.
Avalo Therapeutics executes 1-for-240 reverse stock split to regain Nasdaq compliance
Reverse split effective 5:00 PM ET Dec 28, 2023; shares trade split-adjusted Dec 29 under AVTX.
On June 17, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Rita Jain, M.D. to the Board, effective immediately.
On March 25, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Michael Heffernan to the Board, effective immediately.
On January 2, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025.
On July 16, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Mittie Doyle, M.D., FACR, as Chief Medical Officer, effective July 15, 2024.
On June 24, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Paul Varki as Chief Legal Officer of the Company.
the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024
Jonathan Goldman was appointed to the Board.
the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024
The Board appointed the Company’s President and Chief Executive Officer and Board member, Dr. Garry Neil, M.D., to replace Mr. Boyd as Chairman of the Board.
On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.
On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.
On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.
Max materiality 0.90 · Median 0.60 · Most common event other_material